Joseph Bednarek1, Brianna Traxinger1, Dania Brigham1, Jonathan Roach2, David Orlicky3, Dong Wang1, Roberta Pelanda4, Cara L Mack1. 1. Department of Pediatrics, Section of Gastroenterology, Hepatology and Nutrition, Aurora, CO. 2. Department of Surgery, University of Colorado School of Medicine, Aurora, CO. 3. Department of Pathology, University of Colorado School of Medicine, Aurora, CO. 4. Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO.
Abstract
Biliary atresia (BA) is a neonatal T cell-mediated, inflammatory, sclerosing cholangiopathy. In the rhesus rotavirus (RRV)-induced neonatal mouse model of BA (murine BA), mice lacking B cells do not develop BA, and the lack of B cells is associated with loss of T-cell and macrophage activation. The aim of this study was to determine the mechanism of B cell-mediated immune activation (antigen presentation versus cytokine production) in murine BA. Normal neonatal B cells in the liver are predominantly at pro-B and pre-B cellular development. However, BA mice exhibit a significant increase in the number and activation status of mature liver B cells. Adoptively transferred B cells into RRV-infected, B cell-deficient mice were able to reinstate T-cell and macrophage infiltration and biliary injury. Nonetheless, neonatal liver B cells were incompetent at antigen presentation to T cells. Moreover, 3-83 immunoglobulin transgenic mice, in which B cells only present an irrelevant antigen, developed BA, indicating a B-cell antigen-independent mechanism. B cells from BA mice produced a variety of innate and adaptive immune cytokines associated with immune activation. In vitro trans-well studies revealed that BA B cells secreted cytokines that activated T cells based on increased expression of T-cell activation marker cluster of differentiation 69. Conclusion: Neonatal liver B cells are highly activated in murine BA and contribute to immune activation through production of numerous cytokines involved in innate and adaptive immunity; this work provides increased knowledge on the capacity of neonatal B cells to contribute to an inflammatory disease through cytokine-mediated mechanisms, and future studies should focus on targeting B cells as a therapeutic intervention in human BA.
Biliary atresia (BA) is a neonatal T cell-mediated, inflammatory, sclerosing cholangiopathy. In the rhesus rotavirus (RRV)-induced neonatal mouse model of BA (murineBA), mice lacking B cells do not develop BA, and the lack of B cells is associated with loss of T-cell and macrophage activation. The aim of this study was to determine the mechanism of B cell-mediated immune activation (antigen presentation versus cytokine production) in murineBA. Normal neonatal B cells in the liver are predominantly at pro-B and pre-B cellular development. However, BAmice exhibit a significant increase in the number and activation status of mature liver B cells. Adoptively transferred B cells into RRV-infected, B cell-deficient mice were able to reinstate T-cell and macrophage infiltration and biliary injury. Nonetheless, neonatal liver B cells were incompetent at antigen presentation to T cells. Moreover, 3-83 immunoglobulin transgenic mice, in which B cells only present an irrelevant antigen, developed BA, indicating a B-cell antigen-independent mechanism. B cells from BAmice produced a variety of innate and adaptive immune cytokines associated with immune activation. In vitro trans-well studies revealed that BA B cells secreted cytokines that activated T cells based on increased expression of T-cell activation marker cluster of differentiation 69. Conclusion: Neonatal liver B cells are highly activated in murineBA and contribute to immune activation through production of numerous cytokines involved in innate and adaptive immunity; this work provides increased knowledge on the capacity of neonatal B cells to contribute to an inflammatory disease through cytokine-mediated mechanisms, and future studies should focus on targeting B cells as a therapeutic intervention in humanBA.
Authors: H Noorchashm; Y K Lieu; N Noorchashm; S Y Rostami; S A Greeley; A Schlachterman; H K Song; L E Noto; A M Jevnikar; C F Barker; A Naji Journal: J Immunol Date: 1999-07-15 Impact factor: 5.422
Authors: Cara L Mack; Rebecca M Tucker; Brandy R Lu; Ronald J Sokol; Andrew P Fontenot; Yoshiyuki Ueno; Ronald G Gill Journal: Hepatology Date: 2006-11 Impact factor: 17.425
Authors: Marie Anson; Inês Amado; Marie-Pierre Mailhé; Emmanuel Donnadieu; Sylvie Garcia; François Huetz; Antonio A Freitas Journal: PLoS One Date: 2016-11-23 Impact factor: 3.240
Authors: Sarah A Taylor; Padmini Malladi; Xiaomin Pan; Joshua B Wechsler; Kathryn E Hulse; Harris Perlman; Peter F Whitington Journal: Sci Rep Date: 2019-03-14 Impact factor: 4.379
Authors: Yuhuan Luo; Dania Brigham; Joseph Bednarek; Richard Torres; Dong Wang; Sara Ahmad; Cara L Mack Journal: Hepatology Date: 2021-04-27 Impact factor: 17.425